TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer(National Health Service), Nagy Habib(Hammersmith Hospital), Rose Hodgson(University of Oxford), Jeffrey Yachnin(Karolinska University Hospital), Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Bristi Basu(University of Cambridge), Laura Sinigaglia(Groupe d'Oncologie Radiothérapie Tête et Cou), Bríd M. Ryan(National Institutes of Health), Jon Voutila, Mélanie Grosso(Veracyte (United States)), Daneng Li(City Of Hope National Medical Center), Dimitris Zacharoulis(University Hospital of Larissa), Cheng Ean Chee(National University Cancer Institute, Singapore), John J. Rossi(City of Hope), Nina Raulf(CTI BioPharma (United Kingdom)), Vikash Reebye(Imperial College London), Marcus Smith Noel(University of Rochester), Tim Meyer(The Royal Free Hospital), Mikael H. Sodergren(Imperial College London), Sarah P. Blagden(Churchill Hospital), Natalie Cook(The Christie NHS Foundation Trust), Thomas R. Talbot(Vanderbilt University), Duncan Spalding(Imperial College London), Aurélie Auguste(Veracyte (United States)), Maria Diab(Emory University), Iain A. McNeish(Imperial College London), Debashis Sarker(King's College - North Carolina), Kai‐Wen Huang(National Taiwan University Hospital), Madhava Pai(Imperial College London), T.R. Jeff Evans(Beatson West of Scotland Cancer Centre), Joanna P. Nicholls(Imperial College London), Robert Habib(CTI BioPharma (United Kingdom)), Denis Arnaud(Veracyte (United States)), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jan Henrik Storkholm(Imperial College London), Min-Sun Song
Cited by 12
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k